Need help finding what you are looking for?
Contact Us
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1089964
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1089964
Cell Dissociation Market Size, Share & Trends Analysis By Product, By Tissue, By Type, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
PUBLISHED:
PAGES: 208 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Global Cell Dissociation Market projected to be worth USD 881.48 million by 2030.
According to SPER Market Research, the Cell Dissociation Market estimated to reach USD 881.48 million by 2030 with a CAGR of 13.5%. Growing occurrence of cell-based research, the growing figure of pharmaceutical and biotechnology companies; these are the fuel to the expansion of the market.
Impact of COVID-19 on the Cell Dissociation Market
The outbreak of COVID-19 has a positive impact on the growth of the market.
Scope of the report:
- Market size available for years: 2019-2030
- Base year considered: 2021
- Forecast period: 2022-2030
- Segments covered: By Product, By Tissue, By type, By End-User, By Region
- Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
- Companies Covered: Abeomics, AcceGen, Alstem, Becton, Biological Industries, Capricorn Scientific, Central Drug House, Cytiva, Dickinson and Company, Gemini Bio, Genlantis, Innovative Cell Technologies, Miltenyi Biotec, Neuromics, PromoCell GmbH, Roche Diagnostics, STEMCELL Technologies, Thermo Fisher Scientific, VitaCyte, Worthington Biochemical Corporation
Driver:
Increasing research & development activities in biopharmaceutical companies, encouraging funding scenario for cancer research, growing occurrence and incidence of chronic and infectious diseases, growing focus on personalized medicine, growing government funding for cell-based research; are the key drivers for the market expansion.
Restraint:
Costly cell-based researches, short of of infrastructure for cell-based research in emerging economies, can restraint the expansion of the market.
Opportunity:
Growth opportunities in emerging markets, development in stem cell research, appearance of advanced tissue dissociation enzyme products, recognition of enzyme-free dissociation products over enzymatic dissociation products.
Challenges:
Survival of small players and new entrants, ethical concerns regarding research in cell biology, are the challenges of the market.
Global Cell Dissociation Market, By Product:
Based on the Product, Global Cell Dissociation Market is segmented as; Enzymatic Dissociation Products (Collagenase, DNase, Elastase, Hyaluronidase, Papain, Trypsin), Enzymatic Dissociation Products, Instruments.
Global Cell Dissociation Market, By Tissue:
Based on the Tissue, Global Cell Dissociation Market is segmented as; Connective Tissues, Epithelial Tissues, Other type tissues (skeletal and muscles tissues).
Global Cell Dissociation Market, By Type:
Based on the Type, Global Cell Dissociation Market is segmented as; Cell detachment, Tissue dissociation.
Global Cell Dissociation Market, By End-User:
Based on the End-User, Global Cell Dissociation Market is segmented as; Pharmaceutical and Biotechnology companies, Research and Academics, other end users.
Global Cell Dissociation Market, By Region:
North America owns the biggest share of the market; this is due to the concentration of giant companies and growing research in Pharma and biopharma companies.
Product Code: BIOT2230
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
- 2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Cell Dissociation Market
5. Market variables and outlook
- 5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
- 5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
- 5.4. Heat map analysis
6. Global Cell Dissociation Market, By Product, 2019-2030 (USD Million)
- 6.1. Enzymatic Dissociation Products
- 6.1.1. Collagenase
- 6.1.2. DNase
- 6.1.3. Elastase
- 6.1.4. Hyaluronidase
- 6.1.5. Papain
- 6.1.6. Trypsin
- 6.2. Enzymatic Dissociation Products
- 6.3. Instruments
7. Global Cell Dissociation Market, By Tissue, 2019-2030 (USD Million)
- 7.1. Connective Tissues
- 7.2. Epithelial Tissues
- 7.3. Other type tissues (skeletal and muscles tissues)
8. Global Cell Dissociation Market, By Type, 2019-2030 (USD Million)
- 8.1. Cell detachment
- 8.2. Tissue dissociation
9. Global Cell Dissociation Market, By End-User, 2019-2030 (USD Million)
- 9.1. Pharmaceutical and Biotechnology companies
- 9.2. Research and Academics
- 9.3. other end users
10. Global Cell Dissociation Market, By Region, 2019-2030 (USD Million)
- 10.1. North America
- 10.1.1. United States
- 10.1.2. Canada
- 10.1.3. Mexico
- 10.2. Europe
- 10.2.1. Germany
- 10.2.2. United Kingdom
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
- 10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Australia
- 10.3.5. South Korea
- 10.3.6. Rest of Asia-Pacific
- 10.4. South America
- 10.4.1. Brazil
- 10.4.2. Argentina
- 10.4.3. Rest of South America
- 10.5. Middle East & Africa
- 10.5.1. Kingdom of Saudi Arabia
- 10.5.2. United Arab Emirates
- 10.5.3. Rest of Middle East & Africa
11. Company Profiles
- 11.1. Abeomics
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
- 11.2. AcceGen
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
- 11.3. Alstem
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
- 11.4. Becton
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
- 11.5. Biological Industries
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
- 11.6. Capricorn Scientific
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
- 11.7. Central Drug House
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
- 11.8. Cytiva
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
- 11.9. Dickinson and Company
Company details
Financial outlook
Product summary
Recent developments
- 11.10. Gemini Bio
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
- 11.11. Genlantis
- 11.11.1. Company details
- 11.11.2. Financial outlook
- 11.11.3. Product summary
- 11.11.4. Recent developments
- 11.12. Innovative Cell Technologies
- 11.12.1. Company details
- 11.12.2. Financial outlook
- 11.12.3. Product summary
- 11.12.4. Recent developments
- 11.13. Miltenyi Biotec
- 11.13.1. Company details
- 11.13.2. Financial outlook
- 11.13.3. Product summary
- 11.13.4. Recent developments
- 11.14. Neuromics
- 11.14.1. Company details
- 11.14.2. Financial outlook
- 11.14.3. Product summary
- 11.14.4. Recent developments
- 11.15. PromoCell GmbH
- 11.15.1. Company details
- 11.15.2. Financial outlook
- 11.15.3. Product summary
- 11.15.4. Recent developments
- 11.16. Roche Diagnostics
- 11.16.1. Company details
- 11.16.2. Financial outlook
- 11.16.3. Product summary
- 11.16.4. Recent developments
- 11.17. STEMCELL Technologies
- 11.17.1 Company details
- 11.17.2 Financial outlook
- 11.17.3 Product summary
- 11.17.4 Recent developments
- 11.18. Thermo Fisher Scientific
- 11.18.1. Company details
- 11.18.2. Financial outlook
- 11.18.3. Product summary
- 11.18.4. Recent developments
- 11.19. VitaCyte
- 11.19.1. Company details
- 11.19.2. Financial outlook
- 11.19.3. Product summary
- 11.19.4. Recent developments
- 11.20. Worthington Biochemical Corporation
- 11.20.1. Company details
- 11.20.2. Financial outlook
- 11.20.3. Product summary
- 11.20.4. Recent developments
10. Global Cell Dissociation Market, By Region, 2019-2030 (USD Million)
- 10.1. North America
- 10.1.1. United States
- 10.1.2. Canada
- 10.1.3. Mexico
- 10.2. Europe
- 10.2.1. Germany
- 10.2.2. United Kingdom
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
- 10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Australia
- 10.3.5. South Korea
- 10.3.6. Rest of Asia-Pacific
- 10.4. South America
- 10.4.1. Brazil
- 10.4.2. Argentina
- 10.4.3. Rest of South America
- 10.5. Middle East & Africa
- 10.5.1. Kingdom of Saudi Arabia
- 10.5.2. United Arab Emirates
- 10.5.3. Rest of Middle East & Africa
11. Company Profiles
- 11.1. Abeomics
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
- 11.2. AcceGen
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
- 11.3. Alstem
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
- 11.4. Becton
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
- 11.5. Biological Industries
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
- 11.6. Capricorn Scientific
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
- 11.7. Central Drug House
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
- 11.8. Cytiva
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
- 11.9. Dickinson and Company
Company details
Financial outlook
Product summary
Recent developments
- 11.10. Gemini Bio
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
- 11.11. Genlantis
- 11.11.1. Company details
- 11.11.2. Financial outlook
- 11.11.3. Product summary
- 11.11.4. Recent developments
- 11.12. Innovative Cell Technologies
- 11.12.1. Company details
- 11.12.2. Financial outlook
- 11.12.3. Product summary
- 11.12.4. Recent developments
- 11.13. Miltenyi Biotec
- 11.13.1. Company details
- 11.13.2. Financial outlook
- 11.13.3. Product summary
- 11.13.4. Recent developments
- 11.14. Neuromics
- 11.14.1. Company details
- 11.14.2. Financial outlook
- 11.14.3. Product summary
- 11.14.4. Recent developments
- 11.15. PromoCell GmbH
- 11.15.1. Company details
- 11.15.2. Financial outlook
- 11.15.3. Product summary
- 11.15.4. Recent developments
- 11.16. Roche Diagnostics
- 11.16.1. Company details
- 11.16.2. Financial outlook
- 11.16.3. Product summary
- 11.16.4. Recent developments
- 11.17. STEMCELL Technologies
- 11.17.1 Company details
- 11.17.2 Financial outlook
- 11.17.3 Product summary
- 11.17.4 Recent developments
- 11.18. Thermo Fisher Scientific
- 11.18.1. Company details
- 11.18.2. Financial outlook
- 11.18.3. Product summary
- 11.18.4. Recent developments
- 11.19. VitaCyte
- 11.19.1. Company details
- 11.19.2. Financial outlook
- 11.19.3. Product summary
- 11.19.4. Recent developments
- 11.20. Worthington Biochemical Corporation
- 11.20.1. Company details
- 11.20.2. Financial outlook
- 11.20.3. Product summary
- 11.20.4. Recent developments
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.